Phenotypes Associated with This Genotype

Genotype
MGI:6108900

• Allelic Composition: Tg(CAG-Calr)#Mlk/0; Tg(Myh6-cre/Esr1*)1Liao/0
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

enlarged heart ( J:199413 )

• tamoxifen-treated mice exhibit enlarged cardiac chambers

dilated heart left ventricle ( J:199413 )

• as early as 1 week after tamoxifen treatment, less than 30% of mice show dilatation of the left ventricle chamber

• adult hearts of tamoxifen treated mice exhibit enlarged left ventricle chamber with thinned posterior wall

cardiac interstitial fibrosis ( J:253065 )

• tamoxifen-treated mice develop severe cardiac fibrosis

• treatment of tamoxifen-induced mice with TUDCA, the taurine-conjugated form of ursodeoxycholic acid, reduces cardiac fibrosis

dilated cardiomyopathy ( J:199413 )

• in tamoxifen-treated mice

decreased cardiac muscle contractility ( J:199413 )

• as early as 1 week after tamoxifen treatment, less than 30% of mice show reduced percent ejection fraction

abnormal heart echocardiography feature ( J:199413 )

• echocardiography of tamoxifen-induced mice indicates severe left ventricle dilation, increase in left ventricle internal dimension, decreased systolic function of the left ventricle, and increased Tci index of the left ventricle, an indicator of systolic and diastolic function, prolongation of the isovolumic intervals and shortening of ejection fraction

abnormal heart electrocardiography waveform feature ( J:199413 )

• absence of A-wave indicating a restricted pattern of transmitral flow velocity

prolonged PR interval ( J:199413 )

• tamoxifen-treated mice show a longer PR interval indicating prolonged AV conduction

abnormal P wave ( J:199413 )

• P wave amplitude as a proportion of the QRS amplitude is increased in tamoxifen-treated mice

decreased QRS amplitude ( J:199413 )

• QRS amplitude is reduced in tamoxifen-treated mice

abnormal T wave ( J:199413 )

• tamoxifen-treated mice exhibit a weak T amplitude of electrical impulse

congestive heart failure ( J:199413 )

• in tamoxifen-treated mice

growth/size/body

enlarged heart ( J:199413 )

• tamoxifen-treated mice exhibit enlarged cardiac chambers

decreased body weight ( J:199413 )

• in tamoxifen-treated mice

muscle

dilated cardiomyopathy ( J:199413 )

• in tamoxifen-treated mice

decreased cardiac muscle contractility ( J:199413 )

• as early as 1 week after tamoxifen treatment, less than 30% of mice show reduced percent ejection fraction

cellular

cardiac interstitial fibrosis ( J:253065 )

• tamoxifen-treated mice develop severe cardiac fibrosis

• treatment of tamoxifen-induced mice with TUDCA, the taurine-conjugated form of ursodeoxycholic acid, reduces cardiac fibrosis

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
congestive heart failure		DOID:6000		J:253065